Akademska digitalna zbirka SLovenije - logo
E-resources
Peer reviewed Open access
  • Serum miR371 in testicular ...
    Myklebust, Mette Pernille; Thor, Anna; Rosenlund, Benedikte; Gjengstø, Peder; Karlsdottir, Ása; Brydøy, Marianne; Bercea, Bogdan S.; Olsen, Christian; Johnson, Ida; Berg, Mathilde I.; Langberg, Carl W.; Andreassen, Kristine E.; Kjellman, Anders; Haugnes, Hege S.; Dahl, Olav

    Scientific reports, 08/2021, Volume: 11, Issue: 1
    Journal Article

    Abstract MicroRNA-371a-3p (miR371) has been suggested as a sensitive biomarker in testicular germ cell cancer (TGCC). We aimed to compare miR371 with the classical biomarkers α-fetoprotein (AFP) and β-human chorionic gonadotropin (hCG β ). Overall, 180 patients were prospectively enrolled in the study, with serum samples collected before and after orchiectomy. We compared the use of digital droplet PCR (RT-ddPCR) with the quantitative PCR used by others for detection of miR371. The novel RT-ddPCR protocol showed high performance in detection of miR371 in serum samples. In the study cohort, miR371 was measured using RT-ddPCR. MiR371 detected CS1 of the seminoma and the non-seminoma sub-types with a sensitivity of 87% and 89%, respectively. The total sensitivity was 89%. After orchiectomy, miR371 levels declined in 154 of 159 TGCC cases. The ratio of miR371 pre- and post-orchiectomy was 20.5 in CS1 compared to 6.5 in systemic disease. AFP and hCG β had sensitivities of 52% and 51% in the non-seminomas. MiR371 is a sensitive marker that performs better than the classical markers in all sub-types and clinical stages. Especially for the seminomas CS1, the high sensitivity of miR371 in detecting TGCC cells may have clinical implications.